Substituted thiazoles V. Synthesis and antitumor activity of novel thiazolo[2,3-b]quinazoline and pyrido[4,3-d]thiazolo[3,2-a]pyrimidine analogues

被引:104
作者
Al-Omary, Fatmah A. M. [4 ]
Hassan, Ghada S. [3 ,4 ]
El-Messery, Shahenda M. [2 ]
El-Subbagh, Hussein I. [1 ]
机构
[1] Future Univ, Fac Pharmaceut Sci & Pharmaceut Ind, Dept Pharmaceut Chem, Cairo 12311, Egypt
[2] Mansoura Univ, Fac Pharm, Dept Organ Pharmaceut Chem, Mansoura, Egypt
[3] Mansoura Univ, Fac Pharm, Dept Med Chem, Mansoura, Egypt
[4] King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, Riyadh 11451, Saudi Arabia
关键词
Thiazolo[2,3-b]quinazoline and pyrido[4,3-d]thiazolo[3,2-a]pyrimidine; Antitumor activity; BIOLOGICAL EVALUATION; 2,4-DISUBSTITUTED THIAZOLES; THYMIDYLATE SYNTHASE; AGENTS; DERIVATIVES; ANTICANCER; INHIBITORS; 2,6-BIS(ARYLIDENE)CYCLOHEXANONES; CYTOTOXICITY; ANGIOGENESIS;
D O I
10.1016/j.ejmech.2011.10.023
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel series of thiazolo[2,3-b]quinazoline (14-23, 26 and 27), and pyrido[4,3-d]thiazolo[3,2-a] pyrimidine (34-43, 45 and 46) analogues were designed and synthesized. The obtained compounds were evaluated for their in-vitro antitumor activity at the National Cancer Institute (NCI) 60 cell lines panel assay. Compounds 22, 38, 40 and 41 showed remarkable broad-spectrum antitumor activity. Compounds 22 and 38 are almost nine fold more active than 5-FU, with GI(50), TGI, and LC50 values of 2.5, >100, >100; and 2.4, 9.1, 36.2 mu M, respectively; while 40 and 41 are almost seven fold more active than 5-FU, with GI(50), TGI, and LC50 values of 2.9, 12.4, 46.6 and 3.0, 16.3, 54.0 mu M, respectively. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:65 / 72
页数:8
相关论文
共 33 条
  • [1] Abdel-Hafez AA, 2002, ARZNEIMITTELFORSCH, V52, P833
  • [2] Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents
    Adams, BK
    Ferstl, EM
    Davis, MC
    Herold, M
    Kurtkaya, S
    Camalier, RF
    Hollingshead, MG
    Kaur, G
    Sausville, EA
    Rickles, FR
    Snyder, JP
    Liotta, DC
    Shoji, M
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (14) : 3871 - 3883
  • [3] Synthesis and in vitro antioxidant activity of some new fused pyridine analogs
    Al-Omar, MA
    Youssef, KM
    El-Sherbeny, MA
    Awadalla, SAA
    El-Subbagh, HI
    [J]. ARCHIV DER PHARMAZIE, 2005, 338 (04) : 175 - 180
  • [4] Auerbuch S.D., 1990, CANC CHEMOTHERAPY PR, P314
  • [5] Folate-based inhibitors of thymidylate synthase: Synthesis and antitumor activity of gamma-linked sterically hindered dipeptide analogues of 2-desamino-2-methyl-N-10-propargyl-5,8-dideazafolic acid (ICI 198583)
    Bavetsias, V
    Jackman, AL
    Marriott, JH
    Kimbell, R
    Gibson, W
    Boyle, FT
    Bisset, GMF
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (10) : 1495 - 1510
  • [6] Design and synthesis of cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents
    Bavetsias, V
    Marriott, JH
    Melin, C
    Kimbell, R
    Matusiak, ZS
    Boyle, FT
    Jackman, AL
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (10) : 1910 - 1926
  • [7] Da Settimo A, 1998, EUR J MED CHEM, V33, P685
  • [8] Cytotoxic analogues of 2,6-bis(arylidene)cyclohexanones
    Dimmock, JR
    Padmanilayam, MP
    Zello, GA
    Nienaber, KH
    Allen, TM
    Santos, CL
    De Clercq, E
    Balzarini, J
    Manavathu, EK
    Stables, JP
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2003, 38 (02) : 169 - 177
  • [9] Cytotoxic 2,6-bis(arylidene)cyclohexanones and related compounds
    Dimmock, JR
    Kumar, P
    Nazarali, AJ
    Motaganahalli, NL
    Kowalchuk, TP
    Beazely, MA
    Quail, JW
    Oloo, EO
    Allen, TM
    Szydlowski, J
    DeClercq, E
    Balzarini, J
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2000, 35 (11) : 967 - 977
  • [10] el-Bendary E R, 1998, Boll Chim Farm, V137, P115